STAT

Congress isn’t acting to curb drug prices, so states are stepping up. Here’s how

With little action in Congress, states from California to Vermont are experimenting with ways to try to curb drug prices or shine a light on rising costs.

President Trump has complained that drug makers are getting away with murder — and he may be right.

Despite vociferous complaints from consumers that drug prices are too high, Congress has failed to act. And with few exceptions, the pharmaceutical industry has successfully delayed or thwarted state bills that would force drug makers to explain or justify price hikes.

But that may be starting to change. Last week, of the pharma industry, already has a similar policy in place.  recently began requiring drug makers to disclose pricing data about diabetes medicines. And has a new law that penalizes generic companies for price gouging.

You’re reading a preview, subscribe to read more.

More from STAT

STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Lilly’s Zepbound For Sleep Apnea, The FDA Budget, And More
Eli Lilly reported positive results for Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.

Related Books & Audiobooks